(34.200.243.114)
Users online: 2945    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2018, Volume : 11, Issue : 4
First page : ( 1516) Last page : ( 1521)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2018.00282.2

A Review on the Comparison of Vemurafenib and Dabrafenib in the treatment of Melanoma caused by Mutation of Braf

Jayalakshmi N1, Chowdary Ranadheer P2, Praveen D2, Aanandhi M. Vijey3,*

1Department of Pharmacy Practice, School of Pharmaceutical Sciences, (VISTAS) Vels University, Chennai, India

2 Research Scholar, School of Pharmaceutical Sciences, (VISTAS) Vels University, Chennai, India

3Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, (VISTAS) Vels University, Chennai, India

*Corresponding Author E-mail: hodpchemistry@velsuniv.ac.in

Online published on 24 July, 2018.

Abstract

Metastatic melanoma is one of the most aggressive forms of skin cancer. The mortality rate of this cancer is high. Almost 60% of the melanomas are due to the mutation of BRAF gene. BRAF V600E mutations has been implicated in melanoma genesis by different mechanisms. It occurs due to the improper regulation of the activation of downstream MEK (mitogen activated protein kinase enzyme)/ERK (extra cellular signal related kinase) effectors. In order to overcome the increasing rate of this disease a comparative study has been performed between two ERK/MEK inhibitors namely vemurafenib and dabrafenib and also to understand the relative efficacy and toxicity effect between these two therapeutic modalities.

Top

Keywords

Metastasis, Melanoma, BRAF.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
434,940,355 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.